Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 1, 2013, Pages 44-51

  Rudnicki, Stacy A ^a   Berry, James D ^b   Ingersoll, Evan ^c   Archibald, Don ^c   Cudkowicz, Merit E ^b   Kerr, Douglas A ^d   Dong, Yingwen ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SAB: Knopp Biosciences LLC   (United States)

^d BIOGEN   (United States)

Author keywords

ALSFRS R; Amyotrophic lateral sclerosis; CAFS; Dexpramipexole; Phase II

Indexed keywords

DEXPRAMIPEXOLE; PLACEBO; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCORE; ARTICLE; CLINICAL FEATURE; COMBINED ASSESSMENT OF FUNCTION AND SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; FEMALE; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RATING SCALE; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RECOVERY OF FUNCTION; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84875428371     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/17482968.2012.723723     Document Type: Article

References (23)

1. Rowland LP . R iluzole for the treatment of amyotrophic lateral sclerosis: too soon to tell? N Engl J Med. 1994; 330: 636-7.
2. Sejvar J J, H olman R C, B resee J S, K ochanek K D, Schonberger LB . Amyotrophic lateral sclerosis mortality in the United States, 1979-2001 . Neuroepidemiology. 2005; 25: 144-52.
3. Chio A, L ogroscino G, H ardiman O, S wingler R, Mitchell D, Beghi E, et al . Prognostic factors in ALS: a critical review . Amyotroph Lateral Scler. 2009; 10: 310-23.
4. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G . Prognosis in amyotrophic lateral sclerosis: a population based study . Neurology. 2003; 60: 813-9.
5. Czaplinski A, Y en AA, A ppel SH . F orced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population . J Neurol Neurosurg Psychiatry. 2006; 77: 390-2.
6. Kaufmann P, L evy G, T hompson JL, D elbene ML, B attista V, Gordon PH, et al . The ALSFRS-R predicts survival time in an ALS clinic population . Neurology. 2005; 64: 38-43.
7. Kimura F, F ujimura C, I shida S, N akajima H, F urutama D, Uehara H, et al . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS . Neurology. 2006; 66: 265-7.
8. Kollewe K, M auss U, K rampfl K, P etri S, D engler R, Mohammadi B . ALSFRS-R score and its ratio: a useful predictor for ALS progression . J Neurol Sci. 2008; 275: 69-73.
9. Bruijn L I, C udkowicz M . T herapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies . Expert Rev Neurother. 2006; 6: 417-28.
10. Cozzolino M, F erri A, C arri MT . A myotrophic lateral sclerosis: from current developments in the laboratory to clinical implications . Antioxid Redox Signal. 2008; 10: 405-43.
11. Bensimon G, L acomblez L, M eininger V . A controlled trial of riluzole in amyotrophic lateral sclerosis . ALS/Riluzole Study Group. N Engl J Med. 1994; 330: 585-91.
12. Lacomblez L, B ensimon G, L eigh PN, G uillet P, Meininger V . Dose-ranging study of riluzole in amyotrophic lateral sclerosis . Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347: 1425-31.
13. D uffy LM, C hapman AL, S haw PJ, G rierson AJ . R eview: the role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis . Neuropathol Appl Neurobiol. 2011; 37: 336-52.
14. Dupuis L, Gonzalez de Aguilar JL, E chaniz-Laguna A, Loeffl er JP . Mitochondrial dysfunction in amyotrophic lateral sclerosis also affects skeletal muscle . Muscle Nerve. 2006; 34: 253-4.
15. Cudkowicz M, B ozik ME, I ngersoll EW, M iller R, Mitsumoto H, Shefner J, et al . The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis . Nat Med. 2011; 17: 1652-6.
16. ALS CNTF Treatment Study Phase I-II Group, Brooks B, Sanjak M, Ringel S, England J, Brinkmann J, et al . The ALS functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis . Arch Neurol. 1996; 53: 141-7.
17. Cedarbaum JM, S tambler N, M alta E, F uller C, H ilt D, Thurmond B, et al . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function . BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21.
18. Gordon PH, M oore DH, M iller RG, F lorence J M, Verheijde JL, Doorish C, et al . Effi cacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial . Lancet Neurol. 2007; 6: 1045-53.
19. Miller R, B radley W, C udkowicz M, H ubble J, M eininger V, Mitsumoto H, et al . Phase II/III randomized trial of TCH346 in patients with ALS . Neurology. 2007; 69: 776-84.
20. Rosenfeld J, K ing RM, J ackson CE, B edlack RS, B arohn RJ, Dick A, et al . Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS . Amyotroph Lateral Scler. 2008; 9: 266-72.
21. Gordon PH, C heng B, S alachas F, P radat PF, B runeteau G, Corcia P, et al . Progression in ALS is not linear but is curvilinear . J Neurol . 2010; 257: 1713-7.
22. Finkelstein D M, S choenfeld D A . C ombining mortality and longitudinal measures in clinical trials . Stat Med. 1999; 18: 1341-54.
23. Castrillo-Viguera C, G rasso DL, S impson E, S hefner J, Cudkowicz ME . Clinical signifi cance in the change of decline in ALSFRS-R . Amyotroph Lateral Scler. 2010; 11: 178-80.